NCI is using a stepwise approach to assess the potential of various agents to inhibit, reverse and/or delay the carcinogenic process in various organs. One of the preclinical evaluations of potential chemopreventive agents is the demonstration of agent efficacy in preventing cancer in laboratory animal models. Both carcinogen-induced and transgenic animals are used for this purpose. Another area of preclinical development in chemopreventive agents is the development of surrogate intermediate endpoint biomarkers. Such biomarkers must be translatable to the clinic trial situation in order to shorten the time required to evaluate agents clinically in Phase II trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN43309-10-0-1
Application #
8065612
Study Section
Project Start
2004-05-15
Project End
2011-05-14
Budget Start
Budget End
Support Year
Fiscal Year
2010
Total Cost
$1,016,408
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111